Additionally, in vivo experiments demonstrated that treatment with an IL-6 antibody decreases PD-L1 expression in tumor regions by modulating its glycosylation while enhancing JAK1/nonglycosylated PD-L1 association, JAK1-driven Tyr phosphorylation, and STAT3 recruitment [60]. The gene discussed is STAT3; the disease is neoplasm.